29814 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

which is included in the application kit

for this announcement and also

available from the business or grant and

contracts office at most academic and

research institutions, as well as at: http:/

/forms.psc.gov/forms/PHS/phs.html.

Submissions should include a signed

typewritten original of the application

and two signed photocopies.

Application submissions may not be

faxed or sent electronically.

Dated: May 18, 2001.

Mireille B. Kanda,

Acting Director, Office of Population Affairs.

[FR Doc. 01–13743 Filed 5–31–01; 8:45 am]

BILLING CODE 4150–34–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Notice of Meeting of the Advisory

Committee on Minority Health

AGENCY: Office of the Secretary, Office

of Public Health and Science, Office of

Minority Health, HHS.

ACTION: Notice is given of the second

meeting.

The Advisory Committee on Minority

Health will meet on Thursday, June 21,

2001 from 9:00 am to 5:00 pm, and

Friday, June 22, 2001, from 8:30 am–12

Noon. The meeting will be held at the

Hilton Washington and Towers Hotel,

The State Room, 1919 Connecticut

Avenue, NW., Washington, DC.

The Advisory Committee will discuss

racial and ethnic disparities in health,

as well as, other related issues.

The meeting is open to the public.

There will be an opportunity for public

comment which will be limited to five

minutes per speaker. Individuals who

would like to submit written statements

should mail or fax their comments to

the Office of Minority Health at least

two business days prior to the meeting.

For further information, please

contact Ms. Patricia Norris, Office of

Minority Health, Rockwall II Building,

5515 Security Lane, Suite 1000,

Rockville, Maryland 20852. Phone: 301–

443–5084 Fax: 301–594–0767.

Dated: May 25, 2001.

Nathan Stinson, Jr.,

Deputy Assistant Secretary for Minority

Health.

[FR Doc. 01–13744 Filed 5–31–01; 8:45 am]

BILLING CODE 4150–29–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 01085]

Integrating Prevention Services for

Persons With Bleeding and Clotting

Disorders; Notice of Availability of

Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announces the

availability of fiscal year (FY) 2001

funds for a cooperative agreement

program to demonstrate the

effectiveness of the comprehensive care

model in preventing or reducing

bleeding and clotting disorder related

complications through hemostasis and

thrombosis centers. This program

addresses the ‘‘Healthy People 2010’’

focus areas of access to quality health

services, disability and secondary

conditions, educational and

community-based programs, and public

health infrastructure.

The purpose of the program is to (1)

determine the efficacy of integrated

multi-disciplinary care and prevention

services for persons with hemophilia,

other hereditary bleeding disorders

including women with bleeding

disorders, and thrombophilia to reduce

morbidity and mortality associated with

bleeding and clotting diseases; (2) assess

unmet needs for service delivery and

identify outreach strategies designed to

improve access to care; (3) develop

effective messages aimed at disease

management and prevention; and (4)

foster the development of training

programs to enhance provider skills for

the delivery of hemostasis and

thrombosis care.

B. Eligible Applicants

Applications may be submitted by

public and private nonprofit

organizations and by governments and

their agencies; that is, universities,

colleges, research institutions, hospitals,

other public and private nonprofit

organizations, State and local

governments or their bona fide agents,

and federally recognized Indian tribal

governments, Indian tribes, or Indian

tribal organizations.

Note: Title 2 of the United States Code,

Chapter 26, section 1611 states that an

organization described in section 501(c)(4) of

the Internal Revenue Code of 1986 that

engages in lobbying activities is not eligible

to receive Federal funds constituting an

award, grant, cooperative agreement,

contract, loan, or any other form.

C. Availability of Funds

Approximately $1,000,000 is available

in FY 2001 to fund approximately four

awards. It is expected that the average

award will be $250,000, ranging from

$200,000 to $300,000. It is expected that

the awards will begin on or about

September 30, 2001, and will be made

for a 12-month budget period within a

project period of up to two years. The

funding estimate may change.

Continuation awards within an

approved project period will be made

on the basis of satisfactory progress as

evidenced by required reports and the

availability of funds.

D. Program Requirements

In conducting activities to achieve the

purpose of this program, the recipient

will be responsible for the activities

under 1. (Recipient Activities), and CDC

will be responsible for the activities

listed under 2. (CDC Activities).

1. Recipient Activities

a. Using the principles of the multidisciplinary comprehensive care model

utilized in hemophilia treatment center

prevention programs, implement the

model in a health care setting that

features strong clinical, research,

outreach, education, support and

provider training programs for persons

with hemophilia, other hereditary

bleeding disorders including women

with bleeding disorders, and

thrombophilia.

Specifically:

(1) Identify unmet needs of target

populations and establish outreach

mechanisms to improve access to care

for persons with bleeding and clotting

disorders for the purpose of evaluating

prevention interventions.

(a) Determine strategies that will

address unmet needs, assess the efficacy

of prevention activities and improve

access to under-served populations such

as women with bleeding disorders and

individuals with thrombophilia.

(b) Conduct outreach efforts to

increase prevention intervention

awareness and availability of

comprehensive care among the affected

population and referring providers and

establish referral patterns.

(c) Facilitate communication with

other sub-specialties concerning

awareness and prevention of the

complications of bleeding and clotting

disorders.

(2) Develop and implement a plan

that will provide clinical expertise for

diagnosing underlying causes of

coagulation disorders and provide

management and prevention services.

Experience with bleeding and clotting

Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices 29815

disorders should be a preferred

requirement for clinical expertise.

(3) Collaborate with clinical research

programs designed to improve the

treatment of bleeding and clotting

disorders.

(4) Develop training programs to

educate physicians and other providers

in management of bleeding and clotting

disorders.

b. Develop education and awareness

programs for affected populations to

increase knowledge and assist

consumers in making informed

decisions.

(1) Establish mechanisms for

consumer input and education and

assist in fostering locally based

consumer organizations to assist in care

evaluation.

(2) Develop educational materials and

distribute as needed.

(3) Develop methods (i.e. utilizing

consumers) to assist with the delivery of

prevention messages through peer-led

prevention education, outreach, and

support.

c. Evaluate the model for feasibility

and effectiveness.

(1) Develop appropriate data

collection and evaluation systems to

document unmet needs for integrated

diagnostic, management and prevention

services for persons with hemophilia,

other hereditary bleeding disorders

including women with bleeding

disorders, and thrombophilia.

(2) Establish longitudinal studies to

determine outcomes related to multidisciplinary care management for

persons with coagulation disorders.

(3) Devise consent and protocol for

collection of DNA samples for analysis.

(4) Publish and disseminate program

results.

2. CDC Activities

a. Provide consultation, scientific and

technical assistance in the design and

conduct of the project, including

intervention methods, outcome

measures, and analytic approach, as

requested;

b. Assist in the development of a

research protocol for Institutional

Review Board (IRB) review by all

cooperating institutions participating in

the research project. The CDC IRB will

review and approve the protocol

initially and on at least an annual basis

until the research project is completed.

c. Perform selected laboratory testing

as needed including DNA analysis of

blood samples.

d. Assist in data management, the

analysis of research data, interpretation

and dissemination of research findings,

as requested.

E. Content

Letter of Intent (LOI)

An LOI is required for this program.

The narrative should be no more than 3

single-spaced pages, printed on one

side, with one inch margins, and

unreduced font. Your letter of intent

will be used to enable CDC to plan for

the review, and should include the

following information (1) the program

announcement number 01085, (2) name

and address of institution, and (3) name,

address, and telephone number of

contact person. Notification can be

provided by facsimile, postal mail, or

electronic mail (E-mail).

Application

Use the information in the Program

Requirements, Other Requirements, and

Evaluation Criteria sections to develop

the application content. Your

application will be evaluated on the

criteria listed, so it is important to

follow them in laying out your program

plan. The narrative should be no more

than 20 double-spaced pages, printed on

one side, with one inch margins, and

unreduced font.

F. Submission and Deadline

Letter of Intent (LOI)

On or before June 29, 2001, submit the

LOI to the Grants Management

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

Application

Submit the original and five copies of

PHS–398 (OMB Number 0925–0001)

(adhere to the instructions on the Errata

Instruction Sheet for PHS 398). Forms

are available in the application kit and

at the following Internet address:

www.cdc.gov/od/pgo/forminfo.htm

On or before July 20, 2001, submit the

application to the Grants Management

Specialist identified in the ‘‘Where to

Obtain Additional Information’’ section

of this announcement.

Deadline: Applications shall be

considered as meeting the deadline if

they are either:

(a) Received on or before the deadline

date; or

(b) Sent on or before the deadline date

and received in time for submission to

the independent review group.

(Applicants must request a legibly dated

U.S. Postal Service postmark or obtain

a legibly dated receipt from a

commercial carrier or U.S. Postal

Service. Private metered postmarks shall

not be acceptable as proof of timely

mailing.)

Late Applications: Applications

which do not meet the criteria in (a) or

(b) above are considered late

applications, will not be considered,

and will be returned to the applicant.

G. Evaluation Criteria

Each application will be evaluated

individually against the following

criteria by an independent review group

appointed by CDC.

1. Capacity (25 Points Total)

The extent that the applicant provides

multi-disciplinary, integrated, clinical

and research-based prevention

activities, outreach, education, support

and provider training programs to

persons with hemophilia, other

hereditary bleeding disorders including

women with bleeding disorders, and

thrombophilia.

a. The extent that the applicant

documents and explains the scope and

magnitude of previous experiences in

providing a comprehensive, prevention

program for hemophilia, thrombophilia,

and women’s bleeding disorders

including diagnosis, management,

outreach, education, and data collection

utilizing the multi-disciplinary,

comprehensive care model. The extent

to which these services are prevention

oriented. (15 points)

b. The extent that the applicant

demonstrates a collaborative

relationship with well-established basic

science and clinical research programs

to provide the environment for broad

based training and translation research.

(10 points)

2. Background and Need (15 Points)

The extent that the target populations

and catchment area are described in

terms of known morbidity,

demographics, sources of care, and

existing data collection and

surveillance. The extent the applicant

identifies unmet needs and how they

can appropriately address the issues of

the target communities.

3. Goals and Objectives (10 Points)

The extent that the applicant’s

proposed goals and objectives meet the

required activities specified under

‘‘Recipients Activities’’ and are specific,

measurable, time-phased, and realistic.

4. Methods and Activities (35 Points)

a. The extent that the applicant’s plan

explains how the program activities are

to be conducted and the extent that

prevention methods proposed are: (1)

appropriate to accomplish stated goals

and objectives and (2) feasible within

programmatic and fiscal restrictions. (15

points)

b. The extent to which the applicant

describes and documents the

29816 Federal Register / Vol. 66, No. 106 / Friday, June 1, 2001 / Notices

collaborative efforts of it’s program to

(1) assess efficacy of prevention

activities and (2) develop and

implement prevention programs. (15

points)

c. The extent that the applicant

incorporates gathering and using input

from persons with bleeding disorders

and thrombophilia and their family

members, and local consumer and

community based organizations, and the

applicant’s willingness to cooperate

with consumers in the development and

implementation of prevention services.

(5 points)

5. Program management and evaluation

(15 Points)

a. The extent that management

systems, including types, frequency,

and methods of evaluation are used to

ensure appropriate implementation of

program activities. (5 points)

b. The extent of management

experience for recruiting and

implementing large public health

prevention initiatives. (5 points)

c. The degree to which the applicant

has met the CDC Policy requirements

regarding the inclusion of women,

ethnic, and racial groups in the

proposed research. This includes (1) the

proposed plan for the inclusion of both

sexes and racial and ethnic minority

populations for appropriate

representation; (2) the proposed

justification when representation is

limited or absent; (3) a statement as to

whether the design of the study is

adequate to measure differences when

warranted; and (4) a statement as to

whether the plans for recruitment and

outreach for study participants include

the process of establishing partnerships

with community(ies) and recognition of

mutual benefits. (5 points)

6. Budget (Not Scored)

The extent that the budget is

reasonable and consistent with the

intended use of the cooperative

agreement funds.

7. Human Subjects (Not Scored)

Application must adequately address

the requirements of Title 45 CFR Part 46

for the protection of human subjects.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with the original plus

two copies of—

1. Annual progress reports;

2. Financial status report (FSR), no

more than 90 days after the end of the

budget period; and

3. Final financial and performance

reports, no more than 90 days after the

end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where to Obtain Additional

Information’’ section of this

announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I in the

application kit.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–15 Proof of Non-Profit Status

AR–22 Research Integrity

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 301(a)[42 U.S.C. 241(a)] and

317(k)(2)[42 U.S.C. 247b9k)(2)] of the

Public Health Service Act, as amended.

The Catalog of Federal Domestic

Assistance number is 93.283.

J. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page

Internet address—http://www.cdc.gov

Click on ‘‘Funding’’ then ‘‘Grants and

Cooperative Agreements.’’

To receive additional written

information and to request an

application kit, call 1–888–GRANTS4

(1–888 472–6874). You will be asked to

leave your name and address and will

be instructed to identify the Program

Announcement number of interest.

If you have questions after reviewing

the contents of all the documents,

business management technical

assistance may be obtained from: Merlin

Williams, Grants Management

Specialist, Grants Management Branch,

Procurement and Grants Office, Centers

for Disease Control and Prevention,

2920 Brandywine Road, Room 3000,

MS–K75, Atlanta, GA 30341–4146,

Telephone number: 770–488–2765,

Email: mqw6@cdc.gov.

For program technical assistance,

contact: Sally Crudder, Hemophilia

Treatment Center Program, National

Center for Infectious Diseases, Centers

for Diseases Control and Prevention,

1600 Clifton Road NE, MS–E64, Atlanta,

GA 30333, Telephone Number: 404–

371–5270, Email: sic4@cdc.gov.

Dated: May 25, 2001.

Henry S. Cassell, III,

Acting Director, Procurement and Grants

Office, Centers for Disease Control and

Prevention (CDC).

[FR Doc. 01–13734 Filed 5–31–01; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

[Program Announcement 01102]

Cancer Surveillance Research With

Data Enhancement and Utilization,

Notice of Availability of Funds

A. Purpose

The Centers for Disease Control and

Prevention (CDC) announce the

availability of fiscal year (FY) 2001

funds for a cooperative agreement

program to support priority cancer

surveillance research with data

enhancement and utilization activities.

This program addresses the ‘‘Healthy

People 2010’’ priority areas related to

Cancer.

The purpose of this program is to

utilize data from the National Program

of Cancer Registries (NPCR) to perform

enhanced surveillance and operational

research to include developing,

conducting and evaluating cancer

surveillance research projects targeting

breast, colorectal, prostate, ovarian, and

oral/pharyngeal cancers.

Applicants with interest in innovative

cancer surveillance research activities

are encouraged to apply under this

announcement and, if appropriate, to

partner with universities.

This program consists of 4 parts:

Part I—Breast/Colorectal/Prostate (BCP)

Cancer Patterns of Care (POC),

Recurrence, and Survival (Optional

Breast Cancer Screening Linkage

Component)

The purpose of Part I is to conduct

cancer surveillance research by

comparing detailed clinical information

including stage, diagnostic

investigations used to assess stage

(determinants of stage), and treatment in

large, random samples of patients with

female breast, prostate and colorectal

cancers.

The purpose of the Optional Breast

Cancer Screening Linkage Component is

to validate and assess the completeness

and accuracy of information contained

in the state Breast and Cervical Cancer

Early Detection Program (BCCEDP)

minimum data elements (MDE’s) and to